{{ctm}}{{Drugbox
| drug_name = 
| IUPAC_name        = Methyl ''N''-[(2''S'')-1-[(6''S'')-6-[5-[9,9-Difluoro-7-[2-[(1''S'',2''S'',4''R'')-3-[(2''S'')-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3''H''-benzimidazol-5-yl]fluoren-2-yl]-1''H''-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
| image             = Ledipasvir.svg
| alt               = 
| caption           = 

<!-- Clinical data -->
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_status      = 
| routes_of_administration = 口服

<!-- Pharmacokinetic data -->
| bioavailability   = 76%
| protein_bound     = >99%
| metabolism        = 非[[细胞色素|细胞色素]]代谢
| elimination_half-life = 47小时
| excretion         = 

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number        = 1256388-51-8
| ATCvet            = 
| ATC_prefix        = J05
| ATC_suffix        = AX65
| ATC_supplemental  = ({{link-en|复方索非布韦雷迪帕韦片|Ledipasvir/sofosbuvir}})
| PubChem           = 
| DrugBank          = 
|  ChemSpiderID = 29271894
| ChEBI_Ref = {{ebicite|correct|EBI}} 
| ChEBI = 85089
|  InChI = 1/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1
|  InChIKey = VRTWBAAJJOHBQU-KMWAZVGDBR
|  StdInChI = 1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1
|  StdInChIKey = VRTWBAAJJOHBQU-KMWAZVGDSA-N

<!-- Chemical data -->
| C=49 | H=54 | F=2 | N=8 | O=6
| molecular_weight  = 889.00 g/mol
| smiles = CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
}}

'''雷迪帕韦'''（英语：'''{{lang|en|Ledipasvir}}'''，亦作'''GS-5885'''）是{{link-en|吉利德科学|Gilead Sciences}}研发的治疗[[C型肝炎|C型肝炎]]的药物<ref>{{cite web | url = http://www.ama-assn.org/resources/doc/usan/ledipasvir.pdf | title = Ledipasvir | publisher = United States Adopted Name}}</ref>。在完成了[[Ⅲ期临床试验|Ⅲ期临床试验]]后，吉利德于2014年2月10日向[[美国联邦政府|美国联邦政府]]申请报批了固定剂量复方片剂，{{link-en|复方索非布韦雷迪帕韦片|Ledipasvir/sofosbuvir}}<ref group="注">英文：sofosbuvir/ledipasvir combination tablet，商品名：Harvoni</ref>，用于第1基因型C型肝炎病毒感染的治疗。<ref> {{cite web | url = http://www.gilead.com/news/press-releases/2014/2/gilead-files-for-us-approval-of-ledipasvirsofosbuvir-fixeddose-combination-tablet-for-genotype-1-hepatitis-c#sthash.nk1apkTf.dpuf. | title = Ledipasvir-submitted-to-FDA}}</ref><ref>{{cite web | url = http://www.gilead.com/pipeline | title = GS-5885 | publisher = Gilead Sciences}}</ref>

==參見==
*[[雷迪帕韋/索非布費|雷迪帕韋/索非布費]](Ledipasvir/sofosbuvir,Harvoni )

== 注释 ==
{{reflist|group=注}}

== 参考 ==
{{reflist}}

[[Category:环丙基化合物|Category:环丙基化合物]]
[[Category:咪唑|Category:咪唑]]
[[Category:苯并咪唑|Category:苯并咪唑]]
[[Category:氨基甲酸酯|Category:氨基甲酸酯]]